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Novelty and Impact  
There is a dearth of well-powered studies examining the effect of common germline variants 
associated with colorectal cancer risk on subsequent survival outcomes. Studies using 
additive genetic models failed to reveal robust associations between CRC risk variants and 
survival outcomes. We identified two genetic variants (rs16181980 and rs7495132) with 
significant recessive effects on survival outcomes of colorectal cancer, which provides novel 
insight into genetic architecture of post-diagnosis survival of CRC patients.    
This article is protected by copyright. All rights reserved.
Abstract  
Previous studies using additive genetic models failed to identify robust evidence of 
associations between colorectal cancer (CRC) risk variants and survival outcomes. However, 
additive models can be prone to false negative detection if the underlying inheritance mode is 
recessive. Here, we tested all currently known CRC-risk variants (n=129) in a discovery 
analysis of 5,675 patients from a Scottish cohort. Significant associations were then validated 
in 2,474 CRC cases from UK Biobank. We found that the TT genotype of the intron variant 
rs7495132 in the CRTC3 gene was associated with clinically relevant poorer CRC-specific 
survival in both the discovery (HR=1.97, 95% CI=1.41-2.74, p=6.1x10-5) and validation 
analysis (HR=1.69, 95% CI=1.03-2.79, p=0.038).  In addition, the GG genotype of 
rs10161980 (intronic variant of AL139383.1 lncRNA) was associated with worse overall 
survival in the discovery cohort (HR=1.24, 95% CI=1.10-1.39, p=3.4x10-4) and CRC-specific 
survival in the validation cohort (HR=1.26, 95% CI=1.01-1.56, p=0.040). Our findings show 
that common genetic risk factors can also influence CRC survival outcome.  
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Introduction  
Previous evidence have shown a familial contribution to survival outcomes of colorectal 
cancer (CRC), indicating that heritable germline genetic components can contribute to 
survival outcome1. Statistical association between germline variation and survival should be 
free from confounding and reverse causation, and so could have utility in prediction of cancer 
outcomes. Genetic variants involved in CRC pathogenesis may also influence subsequent 
survival outcomes in affected carriers. However, previous studies of low penetrance common 
genetic variance found inconsistent results using additive genetic models. Hence, no robust 
associations have been established between any common germline variation and CRC 
survival outcome2, 3. Additive models assume a linear relationship between risk and each 
allele and is widely used in genome-wide association studies (GWAS)4. However, simulation 
studies show that the additive approach has low statistical power to identify effects of 
variants with true mode of inheritance being recessive4. We therefore investigated potential 
recessive genetic effects of variants known to be associated with CRC risk, in order to 
determine whether such variants also had recessive effects on survival outcomes.  
 
Materials and Methods  
We tested associations between survival outcomes of CRC patients and a total of 129 known 
genetic variants (linkage disequilibrium r2<0.2) associated with CRC risk reported by two 
recent GWAS analyses4, 5 (details summarised in supplementary Table 1). Technical details 
of genotyping, imputation and quality control steps can be found in previous publications6.   
We studied 5,675 CRC patients with GWAS data from the Study of Colorectal Cancer in 
Scotland (SOCCS) (discovery set). Age at diagnosis, sex and tumour stage were collected as 
covariates. Statistical power of discovery analysis was estimated for variants with varied 
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genotype frequencies and effect sizes using the method proposed by Freedman 7(type I error 
rate=0.0005). The Cox hazards model was employed to estimate hazard ratios (HR) along 
with 95% confidence intervals (CIs) of homozygotes of minor alleles on overall and CRC-
specific survival. We used the false positive rates (FDR) approach to correct for multiple 
testing (p<0.05 was the significance threshold after correction). We checked the proportional 
hazards assumption of the Cox model for each identified variant by testing the association 
between the Schoenfeld residuals and follow-up time using the SOCCS cohort.8 If time-
dependent trends of Schoenfeld residuals were detected (p<0.05), which indicated potential 
violation of the proportional hazards assumption, we fitted a parametric Weibull model to 
estimate the genetic effects on survival outcomes.9 We also explored the associations 
between the 129 included variants and survival outcomes stratified by sex.  
Significant associations identified from the SOCCS were then validated in an independent 
population-based prospective cohort composed of 2,474 incident CRC cases from the UK 
Biobank. Only age at diagnosis and sex were adjusted in the model due to CRC stage being 
unavailable in the UK Biobank. Given different covariates used, meta-analysis combining the 
two cohorts were not performed. Ethics approval of the study cohorts is presented 
elsewhere10. The diagram of patient selection for the two study cohorts is presented in 
supplementary Figure S1.   
 
 
Results and discussion 
Patient characteristics for the study cohorts are presented in Table 1. Given 5,675 included 
cases, the discovery analysis yielded 88% (overall survival) and 66% (CRC-specific survival) 
power for 82 of the 129 (64%) included variants (homozygous genotype frequency > 0.05) to 
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detect a HR of at least 1.50.  Power estimates of variants with varied genotype frequencies 
and effect sizes are presented in supplementary Table S2.  
 
In the discovery analysis, we found 12 variants associated with overall survival and nine 
variants associated with CRC-specific survival at nominal significance (uncorrected p<0.05) 
(Table 2). After FDR correction, we identified that the GG genotype of the variant 
rs10161980 was associated with clinically relevant inferior overall survival (HR=1.24, 95% 
CI=1.10-1.39, uncorrected p=3.4x10-4, FDR corrected p=0.022). However, this effect was not 
significant on CRC-specific survival after FDR correction (HR=1.30, 95% CI=1.11-1.52, 
uncorrected p=0.005, FDR corrected p=0.196). In addition to rs10161980, the TT genotype 
of the variant rs7495132 was significantly associated with worse CRC-specific survival 
(HR=1.97, 95% CI=1.41-2.74, uncorrected p=6.1x10-5, FDR corrected p=0.008), whereas the 
association with overall survival did not survive the FDR correction (HR=1.40, 95% 
CI=1.01-1.93, uncorrected p=0.045, FDR corrected p=0.467).  No significant deviation from 
the proportional hazards assumption was observed for either variants (p>0.05). We then 
validated the two observed signals using the UK Biobank cohort (N=2,474). The GG 
genotype of rs10161980 was significantly associated with worse CRC-specific survival 
(HR=1.26, 95% CI=1.01-1.56, p=0.040), but not significantly associated with overall 
survival (HR=1.21, 95% CI=0.99-1.46, p=0.057). As for the other variant rs7495132, we 
replicated the observed association between the TT genotype and CRC-specific survival in 
the UK Biobank (HR=1.69, 95%CI=1.03-2.79, p=0.038), although no significant effect was 
detected of this variant on overall survival (HR=1.39, 95% CI=0.86-2.25, p=0.179).  Kaplan-
Meier survival estimates of these two variants in both discovery and validation analysis are 
plotted in Figure 1 (CRC-specific survival) and supplementary Figure S2 for overall 
survival.   
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With regard to stratified analysis by sex, the variant rs7495132 remained significantly 
associated with CRC-specific survival of male patients (TT genotype: HR=2.35, 95% 
CI=1.54-3.60, uncorrected p=8.0x10-5, FDR corrected p=0.010) while rs10161980 was 
observed to be associated with overall survival of female patients from the SOCCS cohort 
(GG genotype: HR=1.38, 95% CI=1.15-1.65, uncorrected p=0.001, FDR corrected p=0.041). 
In addition, we identified significant association between the TT genotype of the variant 
rs174537 and worse overall survival among female patients from the SOCCS.  However, we 
failed to validate any of these associations by conducting sex-stratified analysis using the UK 
Biobank cohort (details in supplementary Table S4).   
 
In this study, we identified two CRC-risk variants (rs7495132 and rs10161980) with 
significant effects on survival outcomes of CRC. Notably, both variants, although not 
reaching statistical significance, showed the same direction but smaller magnitude of effects 
in our previous analysis using additive model 2, indicating the underlying recessive model of 
inheritance for these two variants.  
 
The T allele of rs7495132 was identified as a CRC-risk increasing allele in the original 
GWAS meta-analysis6. Located in chromosome 15, rs7495132 is an intron variant of the 
CRTC3 gene which encodes the protein CREB regulated transcription co-activator 3 
(CRTC3) and is associated with Human T cell leukaemia virus infection. According to the 
results of Genotype-Tissue Expression (GTEx) project (https://gtexportal.org/home/), the T 
allele of rs7495132 is associated with lower expression of the CRTC3 gene in multiple 
human tissues such as musculoskeletal tissue and subcutaneous adipose tissue, although no 
significant association is present in colonic tissue. Previous evidence showed that the CRTC3 
protein can regulate energy balance and is associated with weight gain in a mouse model11. 
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To explore the potential role of adiposity in the observed genetic association, we compared 
the BMI level between CRC patients of different rs7495132 genotypes using the UK Biobank 
cohort. However, no significant difference was detected (mean BMI level of TT vs. TC+CC 
genotypes: 27.64 vs. 27.97, p=0.595). We also added BMI as a covariate in the survival 
model, and observed that the BMI level was not associated with survival outcomes (CRC-
specific survival: HR=1.00, 95%CI=0.98-1.02, p=0.938) whilst the genetic association 
between rs7495132 and survival outcomes remained significant in the multivariable model. 
These results could not rule out adiposity as a potential mediator in the observed genetic 
association.  Future research is needed to further reveal the possible biological function of 
rs7495132 in the adiposity-mediated pathway involved in CRC progression.   
 
With respect to the other variant rs10161980, it is an intron variant of the AL139383.1 
LncRNA located in chromosome 13. Currently, little is known for potential biological 
implications of this gene, and there has been a paucity of evidence that rs10161980 can affect 
expression of any genes. Notably, the G allele of rs10161980 was identified as the CRC-risk 
decreasing allele in the original GWAS6.  This indicates that the variant may be involved in 
different biological pathways of CRC carcinogenesis and tumour progression. It should be 
noted that a chance finding could not be confidently excluded despite the validation in our 
study. Therefore, future large population-based studies are also needed to confirm this 
association. 
 
Given the limited sample size of the study cohorts and the number of variants tested, this 
study was underpowered to detect small recessive genetic effects (HR<1.20), especially for 
variants with low homozygous genotype frequencies (<0.30). Another limitation is that 
AJCC stage was not adjusted in replication analysis due to unavailable data. We re-estimate 
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the effects of these two variants in SOCCS adjusted for only age and sex, and the results 
remained statistically significant (supplementary Table S3).  
 
This study identifies two CRC-risk variants (rs10161980 and rs7495132) that have recessive 
genetic effects on survival outcomes of CRC. Currently AJCC stage is used as a blunt 
indicator of the need for adjuvant chemotherapy. The genetic associations discovered in this 
study provide prospects for future investigations to incorporate rs10161980 and rs7495132 
genotypes into individual prediction models for survival outcomes. In addition, our findings 
improve understanding of the genetic architecture for prognosis of CRC patients. Future 
research is warranted to illuminate biological mechanisms through which these two variants 
influence CRC progression. Our findings also suggest that recessive genetic effects should be 
considered in future genetic association studies on survival of CRC.    
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Figure legend  
Figure 1 Kaplan-Meier survival estimates of CRC-specific survival stratified by rs10161980 
and rs7495132 (A: rs10161980 in SOCCS, B: rs10161980 in UK Biobank; C: rs7495132 in 
SOCCS; D: rs7495132 in UK Biobank) 
 
This article is protected by copyright. All rights reserved.
Table 1 Summarised characteristics of the discovery and validation cohorts 
*Continuous variables are presented with median and interquartile range. 
AJCC, the American Joint Committee on Cancer; NA, not available. 
Variables* SOCCS (n=5,675) UK Biobank 
(n=2,474)




AJCC stage   
I 1,005(17.7%) NA
II 1,891(33.3%)  
III 1,995(35.2%)
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Table 2 Summary of associations (p<0.05) between CRC-risk variants and survival outcomes 
of CRC patients in the SOCCS study under a recessive model 
MA, minor allele; RGF, rare genotype frequency; HR, hazard ratio; CI, confidence interval; 
Pfdr, p-values adjusted using the false positive rate approach. OS, overall survival, CSS, 
CRC-specific survival. 
Variant MA RGF HR(95%CI) P(uncorrected) Pfdr
OS
rs10161980 G 0.12 1.24(1.10-1.39) 3.40E-04 0.022
rs174537 T 0.09 1.23(1.07-1.41) 0.003 0.091
rs6066825 G 0.24 1.22(1.07-1.40) 0.003 0.091
rs73975588 C 0.01 0.55(0.35-0.86) 0.009 0.235
rs3087967 C 0.07 0.89(0.82-0.98) 0.014 0.311
rs3217810 T 0.003 1.42(1.06-1.92) 0.021 0.380
rs78341008 C 0.001 1.79(1.08-2.98) 0.024 0.395
rs35509282 A 0.05 0.61(0.40-0.96) 0.030 0.437
rs10951878 T 0.20 0.89(0.80-0.99) 0.035 0.454
rs35360328 A 0.01 1.35(1.01-1.80) 0.041 0.467
rs7495132 T 0.02 1.40(1.01-1.93) 0.045 0.467
rs16892766 C 0.01 0.55(0.30-1.00) 0.049 0.467
CSS
rs7495132 T 0.02 1.97(1.41-2.74) 6.10E-05 0.008
rs6066825 G 0.24 1.30(1.11-1.52) 0.001 0.063
rs10161980 G 0.12 1.22(1.06-1.40) 0.005 0.196
rs9537521 A 0.03 1.22(1.06-1.41) 0.006 0.201
rs4811050 A 0.04 1.38(1.08-1.78) 0.012 0.301
rs35509282 A 0.05 0.52(0.30-0.90) 0.019 0.414
rs10951878 T 0.20 0.87(0.76-0.99) 0.030 0.492
rs3217810 T 0.003 1.47(1.04-2.09) 0.030 0.492
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